Abstract
A low cardiac output state (LCOS) after cardiac surgery has been variously defined in global literature but has a common consensus on the consequence-increased mortality and morbidity. Levosimendan, with its interesting inotropic properties, has been used to combat this situation and has led to many meta-analyses and clinical trials over the years. The bulk of global literature focuses on prescribing levosimendan as an infusion at induction of anaesthesia or in the immediate postoperative period. This study presents data from a 6-year period with the use of levosimendan as a 24-hour preoperative infusion to prevent LCOS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
